Sign In
Buy PRME
$2.92
-0.100 (-3.31%)
At Close: Jul 31, 2026
Kuehn Law Encourages Investors of Prime Medicine, Inc. to Contact Law Firm
12:26pm, Thursday, 30'th Jan 2025
NEW YORK , Jan. 30, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Prime Medicine, Inc. (NASDAQ: PRME) breached the
Prime Medicine's Bristol Myers Partnership Boosts Outlook For Gene Editing Therapies
05:10am, Tuesday, 26'th Nov 2024
Prime Medicine's proprietary Prime Editing platform offers one-time therapeutic solutions, targeting over 90% of genetic conditions across multiple tissues and development stages. PRME's pipeline high
Dublin, Nov. 21, 2024 (GLOBE NEWSWIRE) -- The "Wilson Disease - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering. The report provides comprehensive insights
Prime Medicine to Participate in Upcoming Investor Conferences
04:00pm, Wednesday, 06'th Nov 2024
CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapi
12 High-Growth Stocks That Could Deliver Parabolic Returns
10:00am, Monday, 28'th Oct 2024
These 12 innovative companies could deliver exponential returns over the next quarter century.
Delivery of Prime Editors with a proprietary, universal liver-targeted LNP was well tolerated, with no safety concerns or detectable off-target edits observed across multiple preclinical studies
Why I Keep Buying These 14 Incredible Growth Stocks
09:45am, Wednesday, 16'th Oct 2024
This diverse set of growth stocks offers tremendous opportunities in the fields of AI, space, biotech, and emerging industries.
Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson's Disease, at Upcoming Scientific Meetings
08:00am, Tuesday, 15'th Oct 2024
-- On-track to initiate IND-enabling activities for Wilson's Disease program in 4Q 2024, with IND or CTA filing expected in 1H 2026 -- CAMBRIDGE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Prime Medicin
PRME Stock Rises 11.8% on Collaboration With Bristol Myers
03:46pm, Tuesday, 01'st Oct 2024
Prime Medicine collaborates with Bristol Myers Squibb for the development of T-cell therapies. Shares gain.
Got $100? Consider Buying These 2 Penny Stocks in October
03:19pm, Tuesday, 01'st Oct 2024
You've likely heard that penny stocks are high-risk investments, and if so, you've heard right.
Why Prime Medicine Stock Soared Nearly 12% Higher on Monday
06:08pm, Monday, 30'th Sep 2024
Changes are afoot at the company, and investors welcomed them.
Crude Oil Moves Higher; Prime Medicine Shares Spike Higher
12:17pm, Monday, 30'th Sep 2024
U.S. stocks traded mixed midway through trading, with the Dow Jones index falling more than 200 points during on Monday.
Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline
08:38am, Monday, 30'th Sep 2024
On Monday, Prime Medicine Inc. PRME announced a strategic research collaboration and license agreement with Bristol Myers Squibb & Co BMY to develop reagents for the next generation of ex vivo T-c
Prime Medicine Unveils Strategically Focused Pipeline
07:01am, Monday, 30'th Sep 2024
-- Prioritizing Set of High Value Programs in Core Areas of Focus; Modularity of Prime Editing Platform Expected to Allow Prime Medicine to Generate Follow-on Candidates Rapidly and Efficiently -- --
2 Growth Stocks That Could Make You Richer
08:15am, Wednesday, 28'th Aug 2024
Prime Medicine is pioneering prime-editing technology for genetic disorders, with the potential for long-term growth despite its early-stage status. Rocket Lab USA is capturing market share in the exp
